Questions prioritized by the guideline panel
| Prioritized questions . |
|---|
| Q1: Should individuals with SCD and neurologic injury, including overt stroke, SCI, or abnormal TCD, undergo MSD transplantation? |
| Q2: Should individuals with frequent pain requiring interventions by a health care provider undergo MSD vs standard of care? |
| Q3: Should individuals with recurrent episodes of ACS undergo matched related allogeneic transplantation vs standard of care? |
| Q4: Should individuals with SCD with an indication for HSCT (as above) who do not have an MSD undergo nonmyeloablative transplantation from alternative donor vs standard supportive care? |
| Q5: Should individuals with SCD undergoing allogeneic transplantation receive a TBI-based regimen (low-dose TBI ≤400 cGy) or chemotherapy-based regimen? |
| Q6: Should individuals with SCD and an indication for HSCT (as above) and an MSD receive myeloablative conditioning or RIC or nonmyeloablative conditioning? |
| Q7: Should age be a determining factor for HSCT with an MSD for individuals with SCD with the above indication? |
| Q8: In pediatric patients with SCD, an indication for BM transplantation, and available cryopreserved matched sibling UCB, should myeloablative BM transplantation be used vs myeloablative UCB transplantation? |
| Prioritized questions . |
|---|
| Q1: Should individuals with SCD and neurologic injury, including overt stroke, SCI, or abnormal TCD, undergo MSD transplantation? |
| Q2: Should individuals with frequent pain requiring interventions by a health care provider undergo MSD vs standard of care? |
| Q3: Should individuals with recurrent episodes of ACS undergo matched related allogeneic transplantation vs standard of care? |
| Q4: Should individuals with SCD with an indication for HSCT (as above) who do not have an MSD undergo nonmyeloablative transplantation from alternative donor vs standard supportive care? |
| Q5: Should individuals with SCD undergoing allogeneic transplantation receive a TBI-based regimen (low-dose TBI ≤400 cGy) or chemotherapy-based regimen? |
| Q6: Should individuals with SCD and an indication for HSCT (as above) and an MSD receive myeloablative conditioning or RIC or nonmyeloablative conditioning? |
| Q7: Should age be a determining factor for HSCT with an MSD for individuals with SCD with the above indication? |
| Q8: In pediatric patients with SCD, an indication for BM transplantation, and available cryopreserved matched sibling UCB, should myeloablative BM transplantation be used vs myeloablative UCB transplantation? |
SCI, silent cerebral infarct.